Get started

Financials · ACET

Adicet Bio Inc. (ACET) financials

For the twelve months ended Sep 30, 2026, Adicet Bio Inc. reported $5.01M of revenue and -$91.00M of net income.

Revenue, TTM
$5.01M
Revenue growth, YoY
-20.8%
Net income, TTM
-$91.00M
Net margin
-1817.7%
Free cash flow, TTM
-$80.45M
Cash
$27.11M
P/S
5.70
Market cap
$28.6M
Annual revenue$5.78M
FY2023FY2025
Annual net income-$116.80M
FY2017FY2025
Annual free cash flow-$96.98M
FY2017FY2025

ACET revenue and earnings growth

ACET revenueQ3 2026$972.0K

Quarter YoY
-17.1%
QoQ
-16.8%
FY YoY
-46.1%

ACET revenue was $972.0K in fiscal Q3 2026 (ended Sep 30, 2026), down 17.1% from a year earlier and down 16.8% from the prior quarter. For the full fiscal 2025 it was $5.78M, down 46.1% from fiscal 2024.

ACET net incomeQ3 2026-$18.88M

ACET net income was -$18.88M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$26.86M a year earlier. For the full fiscal 2025 it was -$116.80M, compared with -$117.12M in fiscal 2024.

ACET EPSQ3 2026-$1.76

ACET diluted EPS was -$1.76 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was -$16.95, compared with -$21.33 in fiscal 2024.

ACET free cash flowQ3 2026-$17.98M

ACET free cash flow was -$17.98M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$22.52M a year earlier. For the full fiscal 2025 it was -$96.98M, compared with -$93.50M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
Revenue$5.78M$10.71M$9.98M------
Research and development$99.13M$99.32M$106.04M$71.25M$48.94M$34.33M$23.69M$14.72M$16.84M
Selling, general and admin$22.99M$28.29M$26.53M$26.30M$22.22M$22.76M$8.69M$8.43M$2.04M
Operating income-$122.11M-$127.61M-$152.04M-$72.55M-$61.43M-$39.19M-$31.39M-$14.96M-$18.88M
Interest expense$36.0K$4.0K$25.0K$80.0K$176.0K$134.0K---
Pre-tax income-$116.80M-$117.12M-$142.66M-$69.79M-$62.12M-$39.49M-$28.12M-$9.89M-$33.78M
Income tax$0$0$0$0-$125.0K-$2.81M$19.0K-$589.0K$0
Net income-$116.80M-$117.12M-$142.66M-$69.79M-$62.00M-$36.68M-$28.14M-$9.30M-$33.78M
EPS, basic-$16.95-$21.33-$52.96-$27.20-$32.00-$80.16-$210.40-$76.48-$134.72
EPS, diluted-$16.95-$21.33-$52.96-$27.20-$32.00-$80.16-$210.40-$76.48-$134.72
Diluted shares6.9M5.5M2.7M2.6M1.9M457,498.563133,685.813121,686250,594.563

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
Cash and equivalents$38.92M$59.40M$159.71M$257.66M$277.69M$88.86M$14.89M$9.47M$36.95M
Short-term investments--$0-----$0
Current assets$160.93M$180.14M$162.27M$261.04M$282.44M$100.34M$64.19M$109.53M$55.15M
Goodwill--$0$19.46M$19.46M$20.09M---
Total assets$192.35M$220.22M$207.29M$330.69M$338.94M$153.84M$81.59M$109.94M$55.19M
Current liabilities$21.53M$19.39M$19.29M$19.71M$16.32M$22.48M$14.87M$5.72M$5.50M
Total liabilities$33.15M$33.61M$37.12M$38.35M$35.81M$44.01M$27.87M$5.74M$5.50M
Shareholders' equity$159.21M$186.61M$170.18M$292.34M$303.13M$109.83M-$60.37M-$33.52M-$26.95M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
Operating cash flow-$95.25M-$92.38M-$93.72M-$44.77M-$51.05M-$41.55M-$27.88M-$18.18M-$10.98M
Capital expenditures$1.74M$1.12M$4.46M$16.78M$13.05M$990.0K$1.07M$876.0K$44.0K
Free cash flow-$96.98M-$93.50M-$98.18M-$61.55M-$64.10M-$42.54M-$28.95M-$19.06M-$11.03M
Investing cash flow$2.39M-$119.24M-$4.46M-$16.78M-$2.80M$115.22M-$47.93M-$16.06M-$44.0K
Financing cash flow$75.25M$111.31M$236.0K$41.51M$242.69M$303.0K$76.94M$11.05M$64.38M
Stock-based compensation$14.27M$22.23M$20.26M$17.13M$12.51M$5.26M$1.18M$2.48M$470.0K
Depreciation and amortization$6.38M$6.47M$6.10M$2.58M$1.54M$1.23M$1.24M$1.22M$5.0K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
Revenue growth, YoY-46.1%7.4%-------
Operating margin-2113.8%-1191.1%-1523.7%------
Net margin-2021.9%-1093.2%-1429.7%------
Free cash flow margin-1678.8%-872.7%-984.0%------
Return on equity-73.4%-62.8%-83.8%-23.9%-20.5%-33.4%---
Return on assets-60.7%-53.2%-68.8%-21.1%-18.3%-23.8%-34.5%-8.5%-61.2%
Current ratio7.479.298.4113.2517.314.464.3219.1610.02

Source: XBRL data Adicet Bio Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-16, first reported Mar 12, 2026.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

ACET peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
ACET$5.01M-20.8%-$91.00M-1817.7%$28.6M
LLY$86.46B+45.5%$27.58B31.9%$1.27T
JNJ$99.33B+7.8%$16.09B16.2%$664.95B
ABBV$66.01B+10.7%$10.34B15.7%$514.92B
MRK$67.38B+4.9%$2.45B3.6%$361.71B
NVS$54.53B+8.4%$13.98B25.6%$310.17B
AZN$58.74B+8.6%$10.22B17.4%$289.10B
ABT$48.23B+10.0%$4.70B9.7%$190.39B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$178.51B

ACET FAQ

7 questions
  • What is ACET revenue?
    Adicet Bio Inc. (ACET) reported $5.01M of revenue for the twelve months ended Sep 30, 2026. That is down 20.8% from the year before. Revenue for fiscal 2025 was $5.78M.
  • Is ACET profitable?
    No. Adicet Bio Inc. reported a net loss of $91.00M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does ACET have?
    Adicet Bio Inc. reported $27.11M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is ACET revenue growing?
    Adicet Bio Inc.'s revenue changed -46.1% in fiscal 2025, to $5.78M.
  • What is ACET free cash flow?
    Adicet Bio Inc. generated -$80.45M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$80.14M less capital expenditures.
  • When did ACET last report financial results?
    The latest statements here come from Adicet Bio Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.
  • Where does this ACET financial data come from?
    Quantisnow builds these statements from the structured XBRL data Adicet Bio Inc. files with the SEC. It is provided for information only and is not investment advice.